sanofi glp 1 agonist Emerging Trends in the Development of GLP-1 Receptor Agonists The European Commission Approves Sanofi

Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs

doi: 10.1097/MNH.0b013e328350313e

Open 5 , e2231982 (2022)

The BELIEVE study of bimagrumab + semaglutide

Furthermore, the risks of myocardial infarction (HR 0.91, 95% CI 0.840.98 with GLP-1RAs and HR 0.89, 95% CI 0.800.98 with SGLT2is) and cardiovascular death (HR 0.88, 95% CI 0.800.96 with GLP-1RAs and HR 0.84, 95% CI 0.750.94 with SGLT2is) were similarly reduced in both GLP-1RA and SGLT2i groups, while the risk of stroke was reduced only with GLP-1RAs (HR 0.86, 95% CI 0.770.97 with GLP-1RAs and HR 0.97, 95% CI 0.861.10 with SGLT2is)